drugset / Trial / NCT00578448

Belatacept Pharmacokinetic Trial in Renal Transplantation

NCT00578448

Phase 2 Completed 14 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication

Timeline

Start
2008-03
Primary completion
2009-03
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Belatacept Protein / enzyme biologic 5 mg/kg Intravenous
Comparator Belatacept Protein / enzyme biologic 10 mg/kg Intravenous

Indications

No indication recorded.